Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by cra1gBon Mar 01, 2021 9:46am

102 Views

Post# 32684383

9:45 Level 2

$0.095	330000	5	$0.10	2140000	39
$0.09	1445000	18	$0.105	157000	6
$0.085	1948000	23	$0.11	1016000	20
$0.08	2319000	31	$0.115	765000	10
$0.075	899000	20	$0.12	2493000	22
$0.07	1595000	48	$0.125	147000	5
$0.065	1022000	32	$0.13	763000	17
$0.06	1056000	31	$0.135	621000	9
$0.055	589000	21	$0.14	515000	9
$0.05	1437000	28	$0.145	1000	1